BioLight Life Sciences (BioLight Life Sciences) Capex-to-Revenue : -9.32 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is BioLight Life Sciences Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

BioLight Life Sciences's Capital Expenditure for the six months ended in Dec. 2023 was $0.21 Mil. Its Revenue for the six months ended in Dec. 2023 was $0.02 Mil.

Hence, BioLight Life Sciences's Capex-to-Revenue for the six months ended in Dec. 2023 was -9.32.

BioLight Life Sciences Capex-to-Revenue Historical Data

The historical data trend for BioLight Life Sciences's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLight Life Sciences Capex-to-Revenue Chart

BioLight Life Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Revenue

Get a 7-Day Free Trial

68.50

370.00

1.63

5.29

BioLight Life Sciences Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Capex-to-Revenue	Get a 7-Day Free Trial															-	8.00	0.67	40.89	-9.32

Competitive Comparison of BioLight Life Sciences's Capex-to-Revenue

For the Biotechnology subindustry, BioLight Life Sciences's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLight Life Sciences's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLight Life Sciences's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where BioLight Life Sciences's Capex-to-Revenue falls into.

BioLight Life Sciences Capex-to-Revenue Calculation

BioLight Life Sciences's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.164)	/	0.031
	=	5.29

BioLight Life Sciences's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0.205)	/	0.022
	=	-9.32

BioLight Life Sciences (NAS:BOLT) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

BioLight Life Sciences Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of BioLight Life Sciences's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLight Life Sciences (BioLight Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLight Life Sciences Ltd (NAS:BOLT) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

BOLT:Israel

Address

Kiryat Atidim, Building 7, Entrance 1, 2nd Floor, Tel-Aviv, ISR, 6158101

Website

http://www.bio-light.co.il

BioLight Life Sciences Ltd is an emerging global ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.